title: Alphavirus replicon vaccines.
abstract: The alphavirus replicon technology has been utilized for many years to develop vaccines for both veterinary and human applications. Many developments have been made to the replicon platform recently, resulting in improved safety and efficacy of replicon particle (RP) vaccines. This review provides a broad overview of the replicon technology and safety features of the system and discusses the current literature on RP and replicon-based vaccines.
authors.affiliation: Harrisvaccines Inc., Ames, IA 50010, USA. rvanderveen@harrisvaccines.com
authors.forename: Ryan L
authors.initials: RL
authors.lastname: Vander Veen
authors.forename: D L Hank
authors.initials: DL
authors.lastname: Harris
authors.forename: Kurt I
authors.initials: KI
authors.lastname: Kamrud
mesh_terms: D000524:Alphavirus / Q000235:genetics* / Q000276:immunology* / Q000502:physiology; D018354:Alphavirus Infections / Q000517:prevention & control*; D000818:Animals; D003713:Dendritic Cells / Q000276:immunology / Q000502:physiology / Q000821:virology; D015967:Gene Expression Regulation, Viral; D006801:Humans; D012093:Replicon; D019444:Vaccines, DNA / Q000235:genetics / Q000276:immunology / Q000592:standards; D056189:Viral Tropism; D014765:Viral Vaccines / Q000235:genetics* / Q000276:immunology / Q000592:standards
chemical_list: D019444:Vaccines, DNA; D014765:Viral Vaccines